Accuray Incorporated has achieved a significant milestone by completing 100 patient treatment regimens at Shandong Cancer Hospital and Institute using the Tomo C Radiation Treatment Delivery System. This accomplishment highlights the enhanced clinical capabilities and the potential to provide life-saving treatments to an increasing number of cancer patients in China.
Enhancing Clinical Capabilities
The deployment of the Tomo C System at Shandong Cancer Hospital marks the first implementation of this advanced technology in China. This system, developed through a joint venture between CNNC and Accuray, integrates helical imaging with precise radiation delivery, allowing the hospital to expand its treatment offerings and cater to a broader range of cancer types with greater efficiency.
Meeting Rising Cancer Incidence
With the number of new cancer cases in China projected to surge by nearly 47 percent by 2045, the Tomo C System plays a crucial role in addressing the increasing demand for effective radiotherapy. The system’s ability to deliver up to 95 patient treatment fractions daily significantly boosts the hospital’s capacity to treat more patients, aligning with the country’s urgent need for advanced cancer care solutions.
Inferences:
- The rapid completion of 100 treatments showcases the Tomo C System’s efficiency and reliability in a high-demand environment.
- Accuray’s strategic partnership with CNNC enhances its market presence and technological offerings in the Chinese healthcare sector.
- The successful implementation sets a precedent for other hospitals in China to adopt similar advanced radiotherapy technologies.
Shandong Cancer Hospital and Institute, a premier center for cancer treatment and research in China, serves over 400,000 patients annually. The introduction of the Tomo C System has fortified its reputation by enabling the provision of more precise and personalized cancer treatments, thereby improving patient outcomes and expanding their treatment capabilities.
Accuray’s commitment to innovation is evident in the design of the Tomo C System, which seamlessly integrates imaging, delivery, and data management. This holistic approach ensures that medical teams can deliver fast, ultra-precise treatments, enhancing both the quality of care and operational efficiency within the hospital.
The collaboration between Accuray and CNNC underscores the importance of international partnerships in advancing medical technology. By leveraging local expertise and global innovation, the joint venture has successfully introduced a state-of-the-art radiotherapy system tailored to the specific needs of the Chinese healthcare market.
Accuray’s ongoing efforts to expand its technological footprint in China demonstrate its dedication to addressing the critical needs of the region’s growing cancer patient population. The successful deployment of the Tomo C System at Shandong Cancer Hospital serves as a model for future advancements in radiotherapy and reinforces Accuray’s role as a leader in the medical technology sector.
Accuray’s completion of 100 treatment regimens with the Tomo C System not only signifies a major achievement for the company but also represents a meaningful advancement in cancer care for China. By providing cutting-edge radiotherapy solutions, Accuray is enhancing the capacity of healthcare providers to deliver effective and timely treatments, ultimately contributing to better health outcomes for cancer patients across the country.

This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.